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a b s t r a c t
Objective: The objectives of this review were to identify vaccine economic evaluations that include herd
immunity and describe the methodological approaches used.
Methods: We used Kim and Goldie’s search strategy from a systematic review (1976–2007) of modelling
approaches used in vaccine economic evaluations and additionally searched PubMed/MEDLINE and
Embase for 2007–2015. Studies were classified according to modelling approach used. Methods for esti-
mating herd immunity effects were described, in particular for the static models.
Results: We identified 625 economic evaluations of vaccines against human-transmissible diseases from
1976 to 2015. Of these, 172 (28%) included herd immunity. While 4% of studies included herd immunity
in 2001, 53% of those published in 2015 did this. Pneumococcal, human papilloma and rotavirus vaccines
represented the majority of studies (63%) considering herd immunity. Ninety-five of the 172 studies uti-
lised a static model, 59 applied a dynamic model, eight a hybrid model and ten did not clearly state which
method was used. Relatively crude methods and assumptions were used in the majority of the static
model studies.
Conclusion: The proportion of economic evaluations using a dynamic model has increased in recent years.
However, 55% of the included studies used a static model for estimating herd immunity. Values from a
static model can only be considered reliable if high quality surveillance data are incorporated into the
analysis. Without this, the results are questionable and they should only be included in sensitivity
analysis.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Vaccination confers both direct and indirect effects. The direct
effect implies protection against disease in vaccinated individuals
[1]. Indirect protection is when susceptible individuals avoid infec-
tion because the peoplewho surround them are immunized [2]. The
magnitude of indirect effects is a function of transmissibility of the
infectious agent, population mixing patterns, distribution of
vaccine, and distribution of immunity in the population [3].
‘Herd immunity’ refers to population-scale immunity. The herd
immunity threshold is defined as the proportion of a population that
need to be immune in order to halt the spread of a communicable
disease. The key parameter defining the herd immunity threshold
is R0, which is the number of new infections generated by the first
infectious individual in a completely susceptible population [2]. R0
is affected by duration of infectivity of infected patients, infectious-
ness of the organism, and the number of susceptible people the
infectious carrier is in contact with [3]. Measles is known to have
a relatively high R0 while diseases like Haemophilus influenza type
b and polio spread less easily from person to person [4].
The natural disease mechanisms associated with communicable
diseases require a dynamic model structure to simulate pathogen
transmission among individuals. A dynamic approach captures
both direct and indirect effects by modelling mixing patterns and
risks of infection between vaccinated and unvaccinated individu-
als. Conversely, static models assume constant risk of infection
and are therefore unable to account for disease transmission in
populations. Hence, these are less likely to accurately estimate
the full value of vaccination [5]. Compared to static models,
dynamic models tend to show more favorable incremental cost-
effectiveness ratios [6]. The exception to this is for vaccines where
herd immunity can have a negative impact. This can be due to an
upward shift in the age of the susceptible population or due to ser-
otype replacement. Rubella has for instance substantially more
severe consequences in the first trimester of pregnancy than in
infants and the currently used pneumococcal vaccines lead to ser-
otype replacement, which decreases the overall health impact of
vaccinations. In such situations, a dynamic model would lead to
a less favorable cost-effectiveness ratio than a static model.
In best practice guidelines on economic evaluation of vaccines,
a dynamic model is recommended when the rate at which suscep-
tible individuals acquire infection is reduced due to vaccination or
when it is not possible to obtain a conservative estimate with a sta-
tic model [7,8]. To our knowledge, a systematic review has not yet
assessed to what extent economic evaluations of vaccines consider
herd immunity and if so, which model approach is employed for
this. The objectives of this review were to identify economic eval-
uations of vaccines that include herd immunity and assess which
model properties were used.
2. Methods
2.1. Search strategy and data extraction
The Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines were followed [9]. We
searched PubMed/MEDLINE and Embase. Kim and Goldie con-
ducted a systematic review detailing the modelling approaches
used in cost-effectiveness analyses (CEAs) of vaccines from 1 st
January 1976 to 31 st May 2007 [10]. We adopted their search to
identify CEAs of vaccines from 1 st June 2007 to 31 st July 2015,
and we searched for the same monovalent and multivalent vacci-
nes (Table S1 in the supplement). Kim and Goldie used free text
and MeSH terms, such as vaccin⁄, economic evaluat⁄, humans,
and they limited the search to English language. A detailed descrip-
tion of the search process using rotavirus vaccine as an example is
presented in Table S2. English-language, human vaccine CEAs were
eligible for inclusion if the analysis had an explicit comparator,
included both costs and health effects and presented a decision-
analytic model. Two reviewers independently screened titles and
abstracts and reviewed full-texts to determine inclusion of herd
immunity in either the main analysis (base case) or sensitivity
analysis. Kim & Goldie included 275 CEAs of vaccines in their
review and we also screened these for inclusion of herd immunity.
Vaccination will not induce herd immunity where human trans-
mission (including via a vector) is non-existent. Humans are the
end of the transmission cycle for rabies, Q Fever, Japanese
Encephalitis and Lyme disease and tetanus does not have a trans-
mission cycle. We therefore excluded CEAs of these vaccines.
2.2. Data analysis
Four main categories were used to classify CEA models: Static
(type 1), dynamic (type 2), hybrid (type 3) and ‘model not clearly
stated’ (type 4) (Table 1). Types 1 and 2 were based on Kim and
Goldie’s framework for modelling approaches while type 3 was
defined based on literature, which describes the hybrid model as
combining characteristics of both dynamic and static models
[11,12]. The number of type 1–4 models and associated subtypes
were counted. For each vaccine type, the methods used to estimate
herd immunity were described. We focused this description on the
static models as it is especially for these that the methods are
debatable and not well established. Dynamic models are in con-
trast primarily developed to account for herd immunity. For vac-
cine types with only few studies that included herd immunity,
we also described the methods used in the dynamic models. We
counted the number of CEAs that included herd immunity in their
main analysis versus how many did so in the sensitivity analysis
only (including scenario analyses). We extracted data on time hori-
zon used and compared this between static and dynamic models.
Main health outcomes measures were identified and counted.
Table 1
Classification of model types.
Model types
Type 1: Static (e.g. flow tree, cohort, Markov)
Type 2: Dynamic (e.g. transmission dynamic, SIR, SEIR)
Type 3: Hybrid (e.g. Markov and transmission dynamic)
Type 4: Not clearly stated (classification of model was not possible due to
incomplete description)
Abbreviations: SIR = Susceptible-Infected-Recovered, SEIR = Susceptible-Exposed-
Infectious-Recovered.
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2.3. Quality appraisal of included CEAs
The Consolidated Health Economic Evaluation Reporting Stan-
dards (CHEERS) Statement consisting of 24 requirements was used
[13]. Due to the importance of model choice to accurately predict
herd immunity effects, we focused on item 15, which contains
requirements for modelling: (1) clear description of model, (2) jus-
tification for choice of decision-analytical model, and (3) figure
illustrating model structure provided. Data on the remaining 23
items in CHEERS were also extracted, such as the choice of health
outcomes, measure of effectiveness, and estimation of resources
and costs. For each of the 24 items we assigned a yes/no judgement
and then calculated the total number of confirming items (‘yes’) to
assess the overall quality of each study. Quality was assessed by
two authors independently with disagreements resolved through
discussion.
3. Results
3.1. Paper selection
The PubMed/MEDLINE and Embase databases searches from
2007 to 2015 returned 2215 papers after removing duplicates
(Fig. 1). We screened 640 full-text articles, of which 285 did not
meet the inclusion criteria. Commentaries, methods papers,
reviews and abstracts totalled 195 records, 51 papers focused on
non-vaccine outcomes, such as breastfeeding, stockpiling and
reimbursement, 14 articles were on non-human transmission,
ten articles did not combine costs and effects, eight studies failed
to report on health effects, no model was presented in five articles,
one article was in Czech, and one article was on rabies vaccination
in dogs. We screened 355 CEAs for inclusion of herd immunity and
134 of these were included. Of the 275 articles included in the
Fig. 1. PRISMA flowchart.
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Table 2
Summary of study characteristics (1976–2015).
First author (publication year), by vaccine Model subtype Analysis with herd
immunity
Primary outcome measure Time horizon (years)
Main Sensitivity
Cholera
Jeuland [125] NS Yes Yes DALY 15
Schaetti [126] NS Yes Yes DALY 3
Hepatitis A
Armstrong [127] Cohort Yes Yes QALY Lifetime
Lopez [128] SIR Yes Yes LY 100
Dhankhar [129] TD Yes Yes QALY 100
Hepatitis B
Fenn [130] Markov Yes No LY 25
Williams [131] TD Yes No Cases Lifetime
Hib
Miller [15] NS Yes No DALY Unclear
Jimenez [18] NS No Yes Cases 5
Miller1 [16] NS Yes No DALY Unclear
Zhou [14] Flow tree Yes No QALY 5
Akumu [19] NS No Yes DALY 5
Broughton [17] Flow tree Yes Yes QALY Lifetime
Griffiths [20] Cohort No Yes DALY 6
Clark [21] Flow tree No Yes DALY Lifetime
HPV
Taira [25] TD, Cohort Yes No QALY Lifetime
Elbasha [138,139] TD Yes Yes QALY Lifetime
Goldie [140] TD, Cohort No Yes LY Various
Insinga [141] TD Yes Yes QALY 3
Kim [142] TD Yes Yes LY Lifetime
Chesson [26] TD, Cohort Yes Yes QALY Various
Dasbach [143] TD Yes Yes QALY Various
Goldhaber-Fiebert [22] Markov No Yes QALY Various
Jit [144] TD Yes Yes QALY 100
Kim [145] TD Yes Yes QALY Various
Usher [146] TD Yes No LY 70
Anonychuk [24] Markov Yes Yes QALY Lifetime
Kim [147] TD Yes No QALY 100
Zechmeister [148] TD Yes Yes LY 80
Olsen [149] TD Yes No QALY 62
Vanagas [150] TD Yes No LY 90
Bogaards [151] TD Yes Yes QALY Various
Chessson [152] TD Yes Yes QALY 100
Schobert [153] TD Yes No QALY Lifetime
Vanni [154] TD Yes No QALY Various
Brisson [155] TD Yes No QALY 70
Uusküla [156] TD Yes No QALY 100
Burger [157] TD Yes Yes QALY Lifetime
Laprise [158] TD Yes No QALY 70
Pearson [23] Markov Yes Yes QALY Various
Burger [159] TD Yes Yes QALY Lifetime
Jit [160] TD Yes Yes QALY 100
Influenza
Patriarca [161] Flow tree Yes No Cases 1
Pradas-Velasco [28] SIR, Flow tree Yes No Cases 1
Baguelin [162] SEIR Yes No QALY Lifetime
Sander [29] SIR, Regression analysis No Yes QALY Lifetime
Clements [27] Flow tree No Yes QALY Lifetime
Fisman [163] TD Yes No QALY 10
Baguelin [164] TD Yes Yes QALY 1
Giglio [165] TD Yes No QALY Lifetime
Newall [166] SEIR Yes Yes QALY 1
Pitman [167] TD Yes Yes QALY 150–200
Meeyai [168] TD Yes No DALY 1
Measles
Zwanziger [132] NS Yes No QALY Lifetime
Levin [133] TD Yes No DALY 100
Meningococcal
Bovier [30] Markov Yes Yes LY 30
De Wals [34] Cohort Yes No QALY Lifetime
Rancourt [31] NS Yes No Cases 5
Welte [36] Cohort No Yes QALY 77
Trotter [186] TD Yes Yes QALY 100
De Wals [32] Markov Yes Yes QALY Lifetime
(continued on next page)
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Table 2 (continued)
First author (publication year), by vaccine Model subtype Analysis with herd
immunity
Primary outcome measure Time horizon (years)
Main Sensitivity
Christensen [34] TD, Cohort Yes No QALY 100
Hepkema [35] Flow tree Yes Yes QALY 99
Christensen [169] SIS Yes Yes QALY 100
Tu [33] Markov No Yes QALY Lifetime
Pertussis
Tormans [43] Markov No Yes Cases 6
Beutels [42] Markov Yes Yes QALY 6
Edmunds [170] TD Yes Yes LY Lifetime
Stevenson [41] Markov Yes Yes QALY 5
Caro [40] Cohort Yes Yes QALY Lifetime
Lee [37] Markov No Yes QALY Lifetime
Lee [38] Markov No Yes QALY Lifetime
Lee [39] Markov Yes Yes QALY Lifetime
Coudeville [171] TD Yes Yes LY 100
de Greeff [172] NS Yes No QALY Various
de Vries [173] TD Yes Yes QALY 25
Greer [174] TD, Markov Yes No QALY 10
Rozenbaum [175] TD Yes Yes QALY 25
McGarry [176] TD Yes No QALY 1
Pneumococcal
Melegaro [44] Cohort Yes Yes QALY Lifetime
McIntosh [177] Cohort Yes Yes LY 10
Ray [45] Flow tree Yes Yes LY 5
Wisloff [178] Markov Yes Yes QALY Lifetime
Hubben [46] Flow tree Yes Yes QALY 10
Bergman [47] Markov Yes No LY 100
Lloyd [48] Cohort Yes Yes QALY Lifetime
Tilson [49] Cohort Yes Yes LY 5
Claes [50] Markov Yes Yes QALY 5
Lee [51] Flow tree Yes Yes LY 10
Poirier [52] NS Yes Yes QALY 5
Ray [53] Flow tree Yes Yes LY 5
Silfverdal [54] Cohort Yes Yes LY 10
Vespa [55] Flow tree Yes Yes DALY 10
Chuck [56] Flow tree Yes Yes QALY 1
Giglio [57] Markov Yes Yes LY 76
Kim [83] Markov Yes Yes DALY 5
Rozenbaum [84] Flow tree Yes Yes QALY 5
Rozenbaum [85] Flow tree Yes Yes QALY 5
Rozenbaum [58] Flow tree Yes Yes QALY 5
Rubin [59] Markov Yes Yes QALY 1
Rubin [60] Markov Yes Yes QALY 10
Aljunid [61] Cohort Yes Yes LY 10
Nakamura [62] Flow tree Yes Yes DALY Lifetime
Newall [63] Markov Yes No QALY 100
Robberstad [86] Markov Yes Yes QALY 94
Tyo [64] Markov Yes Yes QALY 5
Uruena2 [96] Flow tree Yes Yes DALY 5
Bin-Chia Wu [65] TD Yes Yes LY 10
Blank [87] Flow tree Yes No QALY 10
Earnshaw [88] Flow tree No Yes QALY Lifetime
Grzesiowski [66] Markov No Yes QALY 35
Hoshi [90] Markov No Yes QALY 5
Knerer [67] Markov Yes No QALY 94
Kuhlmann [68] Markov Yes Yes LY 1
Rozenbaum [179] Cohort Yes Yes QALY 100
Smith [75] Markov Yes Yes QALY Lifetime
Strutton [70] Flow tree Yes Yes QALY 1
Van Hoek [95] TD Yes No QALY 30
Weycker [71] Markov Yes Yes Cases Lifetime
Ayieko [72] Flow tree No Yes DALY 10
Gomez [73] Markov No Yes QALY Lifetime
Hoshi [89] Markov Yes Yes QALY 5
Klok [91] Flow tree Yes Yes QALY 1
Kulpeng [74] Markov Yes Yes QALY Lifetime
Lee [92] Flow tree Yes No QALY 10
Marti [93] Flow tree No Yes QALY Lifetime
Smith [75] Markov Yes Yes QALY 15
Smith et al. [76] Markov Yes Yes QALY Lifetime
Wu [77] Flow tree Yes Yes LY 10
Che [78] Flow tree Yes Yes QALY Lifetime
Hu [76] Flow tree Yes Yes QALY 1
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1976–2007 review by Kim and Goldie, 38 included herd immunity.
Hence, a total of 172 papers were included in the analysis. These
are summarized in Table 2.
3.2. Number of cost-effectiveness analyses including herd immunity
1976–2015
Between 1976 and July 2015 a total of 625 CEAs were published
on vaccines against human-transmissible diseases. Of these, 172
(28%) included herd immunity. In 1993, 2000, 2001 and 2003 less
than 10% of CEAs published in each year incorporated herd immu-
nity (Fig. 2). The highest proportion of CEAs including herd immu-
nity was 53% in 2015. Both the total number of CEAs of vaccines
published and those including herd immunity increased from
2007 onwards compared to earlier years; 80% of the included stud-
ies were published between 2007 and July 2015. One-fifth of the
CEAs that excluded herd immunity mentioned the aspect in their
introduction, methods or discussion section, providing a rationale
for why it was not included, listing it as a limitation or arguing that
modified (more favorable) results would be expected if herd
immunity had been incorporated.
3.3. Number of cost-effectiveness analyses including herd immunity by
vaccine type
Fig. 3 shows the number of CEAs including herd immunity by
vaccine type. Four percent of hepatitis B vaccine, 11% of hepatitis
A and measles vaccines each, 14% of influenza vaccine, 21% of rota-
virus vaccine, 22% of varicella and cholera vaccines each, and 29%
of polio vaccine CEAs included herd immunity. For human papillo-
Table 2 (continued)
First author (publication year), by vaccine Model subtype Analysis with herd
immunity
Primary outcome measure Time horizon (years)
Main Sensitivity
Jiang [79] Markov Yes Yes QALY 100
Vemer [80] Flow tree Yes Yes QALY 5
Caldwell [81] Flow tree Yes Yes QALY 1
Kieninger3 [97] Flow tree Yes Yes DALY 5
Komakhidze4 [98] Flow tree Yes Yes DALY 10
Mezones-Hilguin5 [99] Flow tree Yes Yes DALY 5
Ordonez [82] Flow tree Yes No LY 5
Sibak6 [100] Flow tree Yes Yes DALY 10
Vucina7 [101] Flow tree Yes Yes DALY 20
Polio
Thompson [134] TD Yes No Cases 60
Duintjer Tebbens [135] TD Yes Yes DALY 50
Rotavirus
Jit [180] Cohort Yes No QALY 5
Shim [181] TD Yes Yes QALY 20
Mangen [182] TD, Cohort Yes Yes DALY 20
Rozenbaum [107] Cohort Yes No QALY 5
Syriopoulou [109] Cohort Yes No Cases 5
Atherly [110] Cohort No Yes DALY 5
Atkins [111] TD Yes Yes QALY 50
Bakir [183] Markov Yes No QALY 5
Bruijning-Verhagen [184] Cohort No Yes QALY 20
Tu [108] Cohort Yes No QALY 25
Aidelsburger [112] Markov No Yes QALY 5
de Blasio [185] TD Yes No LY 20
Ahmeti8 [101] Flow tree Yes No DALY Lifetime
Diop9 [103] Flow tree Yes Yes DALY 5
Javanbakht10 [104] Flow tree No Yes DALY 20
Sigei11 [105] Flow tree Yes Yes DALY 5
Uruena12 [106] Flow tree No Yes DALY 5
Varicella
Brisson [113] TD Yes Yes QALY 30
Banz [117] TD Yes Yes Cases 30
Brisson [114] TD Yes Yes QALY 80
Coudeville [121] TD Yes Yes QALY 50
Coudeville [122] TD Yes Yes QALY 50
Lenne [119] TD Yes Yes Cases 50
Hammerschmidt13 [120] TD Yes No Cases 30
Bonanni14 [124] TD Yes No QALY 30
Valentim [123] TD Yes No LY 30
Banz15 [118] TD Yes No Cases 30
Van Hoek [116] TD Yes Yes QALY Infinite
Bilcke [115] TD Yes No QALY Various
Yellow Fever
Monath [136] TD Yes Yes Cases 35
Abbreviations: Hib = Haemophilus influenzae type b, HPV = Human papillomavirus, DALY = Disability-adjusted life year, QALY = Quality-adjusted life year, LY = Life-year, SIR =
Susceptible-Infected-Recovered, NS = Not explicitly stated, TD = Transmission dynamic, SEIR = Susceptible Exposed Infectious Recovered model, SIS = susceptible-infected-
susceptible model.
1 Hib, Hepatitis B, Pneumococcal and Rotavirus vaccines in national immunization schedules.
2–12 The TRIVAC model which is classified as a flow tree was used in these cost-effectiveness analyses [187].
13–15 The Economic Varicella VaccInation Tool for Analysis model (EVITA) which is classified as a transmission dynamic model is used in these cost-effectiveness analyses
[188].
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mavirus (HPV), Haemophilus influenzae type b (Hib), and meningo-
coccal vaccines, herd immunity was presented in 31%, 35% and 40%
of the CEAs, respectively. Nearly half of the CEAs of pneumococcal
vaccine analysed herd immunity while a majority of pertussis CEAs
(61%) considered it. One CEA on yellow fever vaccination was iden-
tified and it considered herd immunity.
3.4. Summary characteristics of cost-effectiveness analyses including
herd immunity
Most CEAs (55%) adopted static models utilising cohort, flow
tree and Markov models (Table 3). The second most commonly
used approach was a transmission dynamic model (34%). Five per-
cent were classified as hybrid CEAs and 6% did not clearly state
which type of model was used. The majority of the CEAs that
included herd immunity did so in the main analysis (86%) and
58% of these varied it in the sensitivity analysis. Fourteen percent
included herd immunity in the sensitivity/scenario analysis only.
Quality-adjusted life years was the most reported primary out-
come measure (62%), followed by disability-adjusted life years
(16%), life-years (15%) and cases (7%).
Time horizons used varied from one year to lifetime. While 87%
of the dynamic models used a time horizon longer than 20 years,
this was done in 45% of the static analyses. A lifetime horizon
was used in 38% and 52% of static and dynamic models, respec-
tively. None of the dynamic models used a 5-year time horizon
while this was the case for 32% of the static models. A 1-year time
horizon was used in 8% and 7% of static and dynamic models,
respectively. The 1-year time horizon was for influenza studies
(n = 5), pertussis (n = 1) and pneumococcal (n = 7).
Fig. 2. Number of vaccine cost-effectiveness analyses including herd immunity, by year 1976–2015 (N = 625).
Fig. 3. Number of cost-effectiveness analyses (CEAs) including herd immunity, by vaccine type (N = 625).Abbreviations: BCG = Bacillus Calmette–Guérin; DTP = diphtheria-
tetanus-pertussis; Hib = Haemophilus influenzae type b; HPV = human papillomavirus; MMR: measles-mumps-rubella. Monovalent, other: Adenovirus, BCG, Typhoid, Rubella,
Mumps. Multivalent: DTP, MMR, Hepatis A-Hepatis B, Pneumoccoal-Influenza, Pneumococcal-Meningoccal.
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3.5. Model approaches for herd immunity
Hib (Haemophilus influenzae type b): Eight CEAs of Hib vaccine
included herd immunity; four in the base case analysis and four
only in scenario analysis. All eight studies used static models. In
the US study by Zhou et al., herd immunity was captured from
surveillance data before and after vaccine introduction [14]. This
was possible because the study was undertaken nine years after
Hib vaccine was introduced. In the 1998 and 2000 papers by Miller
[15,16], herd immunity was reportedly included, but the methods
were not explained and no decision analytic models were pre-
sented. The methods used by Broughton were similarly unclear
[17]. Relatively crude methods were used in the four studies that
only included herd immunity in scenario analyses. Akumu et al.
and Jimenez et al. assumed Hib disease elimination in the long
run [18,19]. Clark et al. and Griffiths et al. assumed that herd
immunity would increase impact by 20% [20,21]. None of these
four studies gave references for the assumptions.
HPV: Of the 27 HPV studies that included herd immunity, 24
did so in the main analysis and three only in the sensitivity analy-
sis. The majority used a disease transmission dynamic approach to
account for herd immunity (78%), with only three studies using a
static model. In the static models used by Goldhaber-Fiebert
et al. (in the sensitivity analysis only) and Pearson et al. (both main
and sensitivity analysis), herd immunity effects were based on
incidence rates derived from previously published dynamic trans-
mission models [22,23]. Similarly, Anonychuk et al. used a Markov
model and attempted to incorporate a conservative estimate of
herd immunity effects in the main and sensitivity analysis by
approximating equations used in a previously published suscepti
ble-infectious-recovered (SIR) dynamic model [24]. Taira et al.,
and Chesson et al. used hybrid models [25,26]. Taira et al. used a
transmission model to simulate the incidence of HPV infection in
the US population of males and females 12–50 years old. The
HPV infection rates predicted by this model were then incorpo-
rated into a probabilistic flow tree model for calculation of HPV
vaccine cost-effectiveness. In a dynamic model, Chesson et al. esti-
mated herd immunity effects for non-vaccinated individuals and a
reduction in genital warts in men as a spill-over effect of female
HPV vaccination. The impact estimates were linked to costs in a
cohort model.
Influenza: We identified 11 influenza vaccine CEAs with herd
immunity, of which nine included it in the base case and two in
the sensitivity analysis only. Dynamic models were commonly
used (63%). Clements et al. presented a flow tree model and
reported that they incorporated herd immunity in the scenario
analysis as disease reduction among unvaccinated persons, but
no additional details on methods were provided [27]. Both
Pradas-Velasco et al. and Sanders et al. used two models; one static
and one dynamic. Pradas-Velasco et al. reported on the results with
and without herd immunity effects, but provided little detail
regarding methods used [28]. In their SIR model, Sander et al.
derived herd immunity as the projected reduction factor for the
change in vaccine coverage estimates from the literature [29].
Meningococcal: Ten meningococcal vaccine CEAs included
herd immunity. Eight of these considered herd immunity in the
main analysis and two only in the sensitivity analysis. Six used sta-
tic models. Bovier et al. used a Markov model and reported herd
immunity effects in both the main and sensitivity analysis, but
the approach was unclear [30]. In other papers, herd immunity
effects were captured by assuming an increase in vaccine effective-
ness [31], reduction in age-specific attack rates in a cohort model
[32], and increase in strain coverage in a Markov model [33]. De
Wals and Erickson undertook a population based cohort study that
enabled them to measure herd immunity directly by comparing
incidence rates in unvaccinated people before and after a mass
immunization campaign [34]. Hepkema et al. used a flow tree
model and herd-immunity effects were obtained by comparing
the serogroup C incidence of 2001 with the average serogroup C
incidence of 2007–2011 [35]. Welte et al. quantified the impact
of herd immunity in the sensitivity analysis in a cohort model by
assuming 50% protection of the unvaccinated [36].
Pertussis: Fourteen CEAs on pertussis vaccine included herd
immunity; 11 in the main and three only in the sensitivity analysis.
Half of the studies applied a static model. In the three CEAs by Lee
et al., Markov models were used and herd immunity was derived
from a published model of transmission dynamics of pertussis
and from published studies of sources of infection of young infants
[37–39]. In the sensitivity analysis, disease reduction from herd
immunity was assumed to depend on vaccination rates in the adult
population and time since last vaccination of the cohort. Based on
assumptions, Caro et al. varied herd immunity effects in infants
from 5% to 35% in a cohort model (with varying effects by age
groups). Due to lack of data on herd immunity, assumptions were
based on expert opinions from the Global Pertussis Initiative and
broad ranges were applied [40]. Stevenson et al. calculated the
probability of infection to vary proportionately to the number
infected within the community [41]. Beutels et al. assumed that
10% of the susceptible part of the population would be indirectly
protected at 70% coverage, whereas at 80% and 90% coverage this
was assumed to be 30% and 70%, respectively [42]. Tormans et al.
used a Markov model and included herd immunity in the sensitiv-
ity analysis only. This was done by assuming that with 45% vacci-
nation coverage, 85–99% of unvaccinated, susceptible children
would be indirectly protected [43].
Pneumococcal:We identified 61 pneumococcal CEAs consider-
ing herd immunity. Fifty-five CEAs included herd immunity in the
base case while six did so in the sensitivity analysis only. These
Table 3
Characteristics of cost-effectiveness analyses including herd immunity (N = 172).
Characteristics N
Model type
Dynamic 59
Static 95
Hybrid 8
Not stated 10
Model subtypes
Transmission dynamic 54
SEIR 2
SIR 1
SIS 1
Cohort 17
Epidemiological 1
Flow tree 40
Markov 36
SIR, Flow tree 2
SIR, Regression 1
TD, Cohort 4
TD, Markov 3
Not stated 10
Herd immunity
Herd immunity in main analysis 148
Herd immunity only in sensitivity analysis 24
Proportion varying herd immunity in sensitivity analysis 99
Primary outcome measure
DALY 27
QALY 106
LY 25
Cases 14
Abbreviations: DALY = Disability-adjusted life year, LY = Life-year, QALY = Quality-
adjusted life year, SEIR = Susceptible Exposed Infectious Recovered model, SIS =
Susceptible-Infected-Susceptible Model, SIR = Susceptible-Infected-Recovered, TD =
Transmission Dynamic.
L.S. Nymark et al. / Vaccine 35 (2017) 6828–6841 6835
mainly used static models (95%). The majority of the studies (38
studies; 62%) estimated herd immunity from US surveillance data
in unvaccinated persons for different age groups [44–82]. Ayieko
et al. also used the US surveillance data to predict the impact of
serotype replacement in Kenyan children. This was done by assum-
ing that children less than 5 years were 1.21 times more likely to
get non-vaccine type disease after PCV introduction [72]. Assump-
tions about the reduction of incidence of invasive pneumococcal
diseases were used to account for herd immunity in 15 CEA studies
[76,83–95]; 12 tested assumptions in sensitivity analyses and 12
derived estimates of herd immunity effects from published litera-
ture. In the CEAs by Uruena et al., Kieninger et al., Komakhidze
et al., Mezones-Hilguin et al., Sibak et al., and Vucina et al. a simple
multiplier was used to calculate a percentage increase in health
benefits due to herd immunity effects [96–101].
Rotavirus: 17 rotavirus vaccine CEAs included herd immunity;
12 in the main analysis and five only in sensitivity analysis.
Seventy-six percent used static models. Ahmeti et al., Diop et al.,
Javanbakht et al., Sigei et al., and Uruena et al. crudely accounted
for herd immunity effects in the static TRIVAC model using a mul-
tiplier and inflating health benefits to 120% of direct effects in chil-
dren <5 years of age [102–106]. In cohort models, Rozenbaum et al.
and Tu et al. presumed herd protection for those not yet protected
by the vaccine and the non-vaccinated, assuming protection would
be as effective as vaccination would be after completing all doses
[107,108]. The implications of this assumption were, however,
not clear. Syriopoulou et al. incorporated herd immunity effects
(from 5% to 10%) into a flow tree model by extending vaccine effi-
cacy [109]. In a scenario analysis, Atherly et al. assumed that
unvaccinated children would receive 15% protection at 50% vacci-
nation coverage [110]. In a transmission dynamic model, Atkins
et al. predicted herd immunity effects to be a 45% reduction in
the probability of infection in unvaccinated individuals at 80% cov-
erage [111]. Aidelsburger et al. used Atkins et al.’s estimate in their
sensitivity analysis in a Markov model [112].
Varicella: 12 varicella vaccine CEAs included herd immunity
and they all used dynamic models. All CEAs included herd immu-
nity in the main analysis. Papers from 2002 and 2003 by Brisson
and Edmunds considered herd immunity effects as post-
immunization shifts in the age of infection in a transmission
dynamic model [113,114]. Bilcke et al. adapted Brisson’s original
model in their 2011 analysis of varicella-zoster vaccination in Bel-
gium [115]. Van Hoek et al. similarly adopted Brisson’s model in
their analysis of varicella vaccination programmes in the UK
[116]. The models used by Banz et al. [117] for Germany, by Banz
et al. [119] for Switzerland, and by Lenne et al. [118] were similarly
age-structured deterministic models based on a set of differential
equations [117-119]. Hammerschmidt et al. (2007) used Banz’s
model to analyse the cost-effectiveness of a two-dose varicella vac-
cine schedule in Germany [120]. In the transmission dynamic mod-
els by Coudeville et al., Valentim et al. and Bonnani et al., transition
probabilities based on time, age of individuals and potential age
shift were used to account for herd immunity [121–124].
Other vaccines: Two CEAs on cholera vaccine with herd immu-
nity were identified; both included it in the main as well as sensi-
tivity analysis. However, neither of the two studies clearly stated
their model type. In the 2009 paper by Jeuland et al., a mathemat-
ical equation linked oral cholera vaccine effectiveness to varying
coverage rates in the study population [125]. Schaetti et al. calcu-
lated herd immunity effects by multiplying the annual incidence of
cases without vaccination with protective efficacy among unvacci-
nated people [126].
Three hepatitis A vaccine CEAs accounted for herd immunity in
both the main and sensitivity analysis. Using a cohort model, Arm-
strong estimated herd immunity from a previously published anal-
ysis of the relationship between vaccination coverage and declines
in hepatitis A incidence [127]. Lopez et al. simulated herd immu-
nity effects in a SIR model by calculating the reduction in force
of infection [128]. Dhankhar et al. used a deterministic, age-
structured transmission dynamic model in which exposure to hep-
atitis A infection were age and time dependent. Contact patterns
between individuals were governed by a conditional probability
mixing matrix [129].
Two hepatitis B vaccine CEAs included herd immunity in the
main, but not in sensitivity analysis. Using a static model, Fenn
et al. assumed a linear relationship between incidence of infection
and prevalence of chronic carriers, which subsequently reduced
infection rates in the non-vaccinated population (herd immunity
effects). The basis for the assumed parameters was not clear
[130]. Williams et al. used an age-structured deterministic model
for analysing hepatitis B virus transmission through sexual contact
and at birth. Targeted versus universal infant vaccination was
assessed on its ability to break the chain of transmission, (referred
to as herd immunity effects) as measured by reduction in chronic
carrier prevalence [131].
Two measles vaccine CEAs considered herd immunity in the
base case, but not in sensitivity analysis. Instead of modelling
measles transmission, Zwanziger et al. [132] used empirical U.S.
data to determine the relationship between measles incidence
and vaccination coverage. The authors assumed that the herd
immunity threshold would be reached with 90% measles vaccine
coverage. Levin et al. [133] evaluated the cost-effectiveness of
measles eradication using a global transmission dynamic model.
The population was stratified by age and infection status of suscep-
tible, exposed, infectious or recovered. Transmission rates varied
seasonally and were based on a matrix of age-specific contact rates
related to household size.
Two polio vaccine CEAs by Thompson and Tebbens [134] and
Duintjer et al. [135] used dynamic transmission models and
included herd immunity in the main, but not in the sensitivity
analysis.
A dynamic model was utilised by Monath and Nasidi [136] in
the CEA of yellow fever vaccine and herd immunity effects esti-
mated from incidence rates were included in both the main and
sensitivity analysis [136].
3.6. Quality assessment
The majority of the 172 included studies (77%) met 20 or more
of the 24 CHEERS checklist criteria. Ten studies satisfied all 24
items, 42 met 23 criteria, 31 conformed to 22 criteria, 29 met 21
criteria, and 20 satisfied 20 items. The mean number across the
172 CEAs was 21 with a range between 12 and 24 items. A com-
plete overview of non-conforming items for individual CEAs is
available in Table S3.
A total of 125 studies (73%) failed to conform to all three com-
ponents in item 15 regarding the choice of model. Thirteen CEAs
failed to provide sufficient description regarding the model used.
Eighty-five CEAs (49%) did not include a graphic figure of the
model structure. Inadequate justification of the model choice was
given in 108 of the 172 CEAs (63%). Forty-six of these studies jus-
tified the choice by using a previously published model. This can
however not be considered an adequate justification; it is neces-
sary to explain why this exact model is considered valuable to
answer the study question.
4. Discussion
There has been an exponential growth in economic evaluations
of vaccines during the past two decades [137]. We found that this
development was mirrored by considerably more studies of newer
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vaccines compared to traditional vaccines. The proportion of stud-
ies that included herd immunity has increased in recent years in
line with the growth in economic evaluation studies in general.
Herd immunity effects were not considered in 72% of vaccine CEAs
published between 1976 and 2015. However, the number of CEAs
including herd immunity has increased nearly fourfold since 2007,
with 80% of included studies being published during 2007–2015.
We identified a total of 172 vaccine CEAs that included herd
immunity.
This is the first review to evaluate the inclusion of herd immu-
nity for all published vaccine CEAs. We however only included
English language articles in our search and we acknowledge this
as a limitation. There are numerous vaccine specific reviews avail-
able and some of these have assessed the inclusion of herd
immunity.
We found marked differences among vaccine types with regard
to the total number of studies and the likelihood of herd immunity
being included. From a technical viewpoint, the importance of
including herd immunity should depend on (i) whether the rate
at which susceptible individuals acquire infection is reduced due
to vaccination and/or (ii) whether it is not possible to obtain a con-
servative estimate with a static model [7,8]. The effective repro-
ductive rate depends on contact patterns between susceptible,
vaccinated, and infectious individuals, and coverage rates. Vaccina-
tion targeted at a specific risk group, such as hepatitis A in trav-
ellers, will for instance not alter the reproductive rate. Herd
immunity will on the other hand always occur when vaccination
targets an epidemiologically influential subgroup, though infants
are only an important subgroup for certain infections (e.g. pneu-
mococcus). Hence, while the first principle is a valid reason for
exclusion of herd immunity, incorporation of herd immunity
effects would in no doubt be warranted in the large majority of
studies following the second principle.
We believe that the inclusion of herd immunity is driven by four
main factors: (1) Growth in dynamic modelling expertise is an
important reason for the rise in inclusion of herd immunity since
2007, including the availability of computer simulation power.
However, infectious disease modelling is still a highly-specialized
field and this capacity is not available to the majority of health eco-
nomic researchers, (2) The extent towhich herd immunity is under-
stood also influences the decision to include these effects. The link
between carriage and Hib disease is for instance not well estab-
lished, which explains why there are no Hib CEAs using dynamic
models. Similarly, herd immunity protection from rotavirus was
not recognized until post-marketing data became available, (3) If
uncertainty concerning the cost-effectiveness of the vaccine exists,
herd immunitymay not be included. Pneumococcal vaccinemay for
instance only be cost-effective if indirect effects on the elderly are
included, and (4) The availability of funding will likely matter since
building a transmission dynamic model is a substantially greater
undertaking than a static model, costs will be higher and sufficient
funding is essential.
We showed that 55% of the 172 studies used a static model for
estimating herd immunity. There are no recommended methods
available for incorporating herd immunity using a static model
and the reliability of these results is questionable. We found that
the static models incorporated herd immunity in four different
ways: (1) By assuming a percentage increase in vaccine impact,
(2) by increasing the vaccine efficacy value, (3) by using herd
immunity impact published by dynamic models and (4) by esti-
mating herd immunity impact from surveillance data or
population-based cohort studies. Among the methods identified
for static models only the use of high quality surveillance data is
defensible.
Results produced by static models must be interpreted with
caveats unless high quality surveillance data are available, in
which case uncertainty is reduced. For each study, researchers
need to assess whether the additional benefits of a dynamic model
outweigh the additional costs and efforts needed to build it. The
additional benefits of including herd immunity effects by way of
a dynamic model are likely higher in the absence of good surveil-
lance data and when a more accurate/comprehensive analysis
could potentially affect decision-making. The latter could be the
case when cost-effectiveness considering only direct effects is in
doubt or when competition between producers of vaccines is high
and any additional benefit counts.
Since the uncertainty about long term impacts are inherently
greater when indirect effects are not implicitly included in the
model, it is warranted that substantially shorter time horizons
were used in the static compared to the dynamic models. Static
models are not able to predict the potential long term increase in
herpes zoster incidence in the elderly following introduction of
varicella vaccination for children. Brisson et al. showed that
although the overall burden of varicella would be significantly
reduced in the UK following infant vaccination, these benefits will
be offset by a rise in zoster morbidity, which would last more than
60 years [138,139]. Hence, a dynamic model is especially required
for a disease like varicella where a vaccine can lead to long term
negative impacts.
Nearly two-thirds of the CEAs lacked sufficient justification for
model choice scored according to the CHEERS guideline. This indi-
cate that further attention is still required to ensure that guideline
standards are adhered to. The lack of clear reporting on reasons for
model choice impedes our ability to understand if herd immunity
effects have been accounted for accurately.
5. Conclusion
Only 28% of the CEAs of vaccines in this review included herd
immunity effects. 55% of the CEAs used static models, which can-
not accurately predict herd immunity. Crude methods and
assumptions were used in the static models to get a rough estimate
of herd immunity.
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